Debio 1347 is a type I1/2B inhibitor selective for FGFR1-3 that was evaluated in a phase I study (NCT01948297) in patients with iCCA (n = 9) with FGFR2 translocation (n = 5), FGFR1 translocation (n = 1), FGFR2 mutation (n = 1), FGFR2 activating deletion (n = 1), and FGFR3 mutation (n = 1). Here, FGFR3 is linked to infantile convulsions and choreoathetosis.